OneSource's partner Orbicular secured tentative US FDA ANDA approval for generic Ozempic (Semaglutide Injection).
OneSource served as CDMO partner providing end-to-end manufacturing from its US-FDA approved Bangalore facility.
The approval highlights OneSource's strategic position in complex drug-device combinations and specialty pharmaceuticals.
This collaboration demonstrates an integrated development-to-submission model for complex peptide products.